Stocktoria

IRIDEX CORP IRIX

Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-8.01
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2026$52.7M-$4.4M$19.2M-$2.3M$4.9M
2024$48.7M-$8.9M$19.5M-$7.3M$2.1M
2023$51.9M-$9.6M$21.8M-$6.9M$9.5M
2022$57.0M-$7.5M$25.4M-$9.8M$17.2M
2022$53.9M-$5.2M$22.8M$8.0M$23.3M
2021$36.3M-$6.3M$15.6M-$3.3M$17.4M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Dizon Romeo RChief Financial Officer2026-06-13Tax withheld2,691$1.12
Mercer PatrickPresident and CEO2026-06-13Tax withheld3,990$1.12
Dizon Romeo RChief Financial Officer2026-06-12Buy975$1.14
Dizon Romeo RChief Financial Officer2026-06-11Buy1,675$1.14
Dizon Romeo RChief Financial Officer2026-06-08Buy2,400$1.12
Dizon Romeo RChief Financial Officer2026-06-05Buy2,521$1.15
Dizon Romeo RChief Financial Officer2026-06-03Buy2,400$1.17
Mercer PatrickPresident and CEO2026-05-26Tax withheld19,233$1.01

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -8.01 (distress)

  • Working capital / assets 0.413
  • Retained earnings / assets -3.171
  • EBIT / assets -0.088
  • Equity / liabilities 0.203

Source: SEC EDGAR filings · CIK 0001006045 · as of 2026-01-03. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.